NASDAQ, ARRY - Array Technologies Inc
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery,
development and commercialization of targeted small molecule drugs to treat
cancer and inflammatory diseases. Our proprietary drug development pipeline
includes clinical candidates that are designed to regulate therapeutically
important target proteins and are aimed at large market opportunities. We
currently have 10 programs in our development pipeline, eight of which are
wholly owned by us.
Our eight most advanced development programs that we wholly own and control
consist of ARRY-543, an ErbB-2/EFGR dual inhibitor for cancer; ARRY-162, a MEK
inhibitor for inflammation; ARRY-797, a p38 inhibitor for inflammation and for
cancer; ARRY-520, a KSP inhibitor for cancer; ARRY-380, an ErbB-2 inhibitor for
cancer; and ARRY-614, a p38/Tie 2 dual inhibitor for inflammation and for
cancer. ...
Read SEC Filing on NASDAQ.com »